Differential Therapeutic Effects of Nateglinide and Acarbose on Fasting and Postprandial Lipid Profiles: A Randomized Trial

Zhou, Jian; Deng, Zihao; Lu, Jingyi; Li, Hong; Zhang, Xiuzhen; Peng, Yongde; Mo, Yifei; Bao, Yuqian; Wang, Jia

doi:10.1089/dia.2014.0299

Cited by 5 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a meta-analysis of placebo-controlled trials, acarbose did not significantly alter total cholesterol levels, but was associated with reductions in TG and increases in HDL-C levels [ 37 ]. In a multicenter, open-label, randomized controlled trial of acarbose compared with nateglinide in Chinese patients with T2DM, neither drug had significant effects on total cholesterol, HDL-C, LDL-C, or non-HDL-C levels; however, acarbose was associated with significantly greater reductions in fasting and postprandial TG levels compared with nateglinide [ 87 ]. In a multicenter, randomized clinical trial, patients with impaired glucose tolerance (a key component of prediabetes) who received acarbose had a 49 % relative risk reduction in the development of CV events, and a 91 % relative risk reduction in MI compared to controls [ 88 ].…”

Section: Introductionmentioning

confidence: 99%

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?

Rosenblit

2016

Cardiovasc Diabetol

View full text Add to dashboard Cite

Dyslipidemia is the most fundamental risk factor for atherosclerotic cardiovascular disease (ASCVD). In clinical practice, many commonly prescribed medications can alter the patient’s lipid profile and, potentially, the risk for ASCVD—either favorably or unfavorably. The dyslipidemia observed in type 2 diabetes mellitus (T2DM) can be characterized as both ominous and cryptic, in terms of unrecognized, disproportionately elevated atherogenic cholesterol particle concentrations, in spite of deceptively and relatively lower levels of low-density lipoprotein cholesterol (LDL-C). Several factors, most notably insulin resistance, associated with the unfavorable discordance of elevated triglyceride (TG) levels and low levels of high-density lipoprotein cholesterol (HDL-C), have been shown to correlate with an increased risk/number of ASCVD events in patients with T2DM. This review focuses on known changes in the routine lipid profile (LDL-C, TGs, and HDL-C) observed with commonly prescribed medications for patients with T2DM, including antihyperglycemic agents, antihypertensive agents, weight loss medications, antibiotics, analgesics, oral contraceptives, and hormone replacement therapies. Given that the risk of ASCVD is already elevated for patients with T2DM, the use of polypharmacy may warrant close observation of overall alterations through ongoing lipid-panel monitoring. Ultimately, the goal is to reduce levels of atherogenic cholesterol particles and thus the patient’s absolute risk.

show abstract

Section: Introductionmentioning

confidence: 99%

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?

Rosenblit

2016

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

Detecting possibly incorrect medication using an unlikely co-occurrences measure

Iacob

Jimoh

Mamun

2017

2017 9th International Conference on Electronics, Computers and Artificial Intelligence (ECAI)

View full text Add to dashboard Cite

The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials

Yousefi,

Fateh,

Nikbaf-Shandiz

et al. 2023

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

PurposeDyslipidemia, characterized by elevated levels of triglycerides (TG), low-density lipoprotein (LDL), total cholesterol (TC), and reduced levels of high-density lipoprotein (HDL), is a major risk factor for cardiovascular diseases (CVD). Several studies have shown the potential of acarbose in improving serum lipid markers. However, there have been conflicting results on the topic in adults. Therefore, a comprehensive systematic review and meta-analysis was conducted to assess the impact of acarbose on lipid profiles.MethodsThe random-effects approach was used to combine the data, and the results were provided as weighted mean difference (WMD) with 95% confidence intervals (CI).ResultsOur meta-analysis included a total of 74 studies with a combined sample size of 7046 participants. The results of the analysis showed that acarbose resulted in a reduction in levels of TG (WMD = − 13.43 mg/dl, 95% CI: − 19.20, − 7.67;P < 0.001) and TC (WMD = − 1.93 mg/dl, 95% CI: − 3.71, − 0.15;P = 0.033), but did not affect other lipid markers. When conducting a nonlinear dose-response analysis, we found that acarbose was associated with an increase in levels of HDL (coefficients = 0.50,P = 0.012), with the highest increase observed at a dosage of 400 mg/d. Furthermore, our findings suggested a non-linear relationship between the duration of the intervention and TC (coefficients = − 18.00,P = 0.032), with a decline observed after 50 weeks of treatment.ConclusionThe findings of this study suggest that acarbose can reduce serum levels of TG and TC. However, no significant effects were observed on LDL or HDL levels.

show abstract

Differential Therapeutic Effects of Nateglinide and Acarbose on Fasting and Postprandial Lipid Profiles: A Randomized Trial

Abstract: Compared with nateglinide, acarbose has superior therapeutic efficacy for reducing fasting and postprandial TG levels in patients with T2DM.

Cited by 5 publications

References 23 publications

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?

Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?

Detecting possibly incorrect medication using an unlikely co-occurrences measure

The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials

Contact Info

Product

Resources

About